Roman Fleck

Board Member, Index Ventures, Geneva

 

Roman joined the life science team of Index Ventures in early 2006 and is a Principal based in the Geneva office. Prior to joining Index he worked for seven years at Boehringer Ingelheim Pharmaceuticals where he held roles of increasing responsibility in preclinical drug discovery in the areas of inflammation and cardiovascular therapies as well as later on in business development. Under his leadership several compounds were moved into clinical development.

Roman received his Ph.D. in organic chemistry from the Massachusetts Institute of Technology (MIT) where he performed research on catalytic antibodies. His research efforts resulted in many publications in prestigious journals, as well as issued patents and patent applications. In addition, he was awarded an MBA from New York University's Stern School of Business where he continues to serve as a mentor for aspiring entrepreneurs.

Currently, he serves on the boards of GlycoVaxyn and Versartis, while remaining closely involved with Funxional Therapeutics, Normoxys, and OncoEthix.